This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
NUS Stock Trading Below 200 & 50-Day SMA: What Should You Do Now?
by Zacks Equity Research
Nu Skin is encountering persistent macroeconomic obstacles, weighing on consumer spending and customer acquisition.
Nu Skin Trading Near 52-Week Low: Should You Buy or Sell NUS Stock?
by Zacks Equity Research
Nu Skin is facing macroeconomic difficulties and a slow-moving direct-selling market. Foreign currency headwinds are also weighing on NUS.
NUS Stock Hurt by Customer Acquisition Challenges: How to Play Ahead?
by Zacks Equity Research
Nu Skin encounters macroeconomic challenges related to volatile consumer spending and strong currency headwinds.
Nu Skin (NUS) Down 28% in 3 Months: What's the Next Best Move?
by Zacks Equity Research
Nu Skin (NUS) has been battling persistent macroeconomic headwinds, which have been weighing on consumer spending and customer acquisition. Strong currency headwinds are also playing foul.
Are Options Traders Betting on a Big Move in Nu Skin (NUS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Nu Skin (NUS) stock based on the movements in the options market lately.
Nu Skin (NUS) Trims FY24 View Despite Q2 Earnings Beat
by Zacks Equity Research
Nu Skin's (NUS) second-quarter 2024 results reflect lower earnings and net sales amid a dynamic macro-environment. Management lowers the 2024 guidance range.
Nu Skin Enterprises (NUS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 16.67% and 2.11%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Nu Skin (NUS) Set to Report Q2 Earnings: What to Expect?
by Zacks Equity Research
Nu Skin's (NUS) Q2 results are likely to reflect the impacts of macroeconomic challenges, including inflation and adverse currency fluctuations.
Nu Skin (NUS) Navigates a Tough Landscape on Growth Strategies
by Zacks Equity Research
Nu Skin (NUS) has been dealing with challenges related to customer and affiliate acquisition. However, product launches, technological advancements and strength in the Rhyz business bode well.
Nu Skin (NUS) Troubled by Customer Acquisition Challenges
by Zacks Equity Research
Nu Skin (NUS) has been battling persistent macroeconomic headwinds across most regions, which has affected customer and affiliate acquisition.
Nu Skin (NUS) Up 5.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin (NUS) Q1 Earnings Beat, Revenues Hurt by Currency Woes
by Zacks Equity Research
Nu Skin's (NUS) first-quarter 2024 results reflect challenges related to volatile currency movements, while cost-management efforts work well.
Nu Skin Enterprises (NUS) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 80% and 3.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Nu Skin (NUS) Q1 Earnings Coming Up: Factors to Consider
by Zacks Equity Research
Nu Skin's (NUS) first-quarter 2024 earnings will likely reflect the adverse impact of macroeconomic challenges like a slowdown in consumer spending. Unfavorable currency translations are a concern.
Is Invesco High Yield Equity Dividend Achievers ETF (PEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PEY
Why Is Inter Parfums (IPAR) Down 4.1% Since Last Earnings Report?
by Zacks Equity Research
Inter Parfums (IPAR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin (NUS) Down 7.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin (NUS) Down More Than 25% in 3 Months: Here's Why
by Zacks Equity Research
Nu Skin (NUS) is battling macroeconomic challenges, with inflation putting pressure on consumer spending and customer acquisition. Management expects revenues to decline in 2024.
Nu Skin (NUS) Q4 Earnings Top Estimates, Revenues Decline Y/Y
by Zacks Equity Research
Nu Skin's (NUS) fourth-quarter 2023 results reflect the persistence of macroeconomic challenges and hurdles related to business transformation, offset by growth in some regions.
Nu Skin Enterprises (NUS) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 27.59% and 1.94%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Things to Consider Ahead of Nu Skin's (NUS) Q4 Earnings
by Zacks Equity Research
Nu Skin's (NUS) fourth-quarter 2023 earnings will likely reflect the adverse impact of macroeconomic challenges like a slowdown in consumer spending. Unfavorable currency translations pose concerns.
Philip Morris (PM) Lags Q4 Earnings Estimates
by Zacks Equity Research
Philip Morris (PM) delivered earnings and revenue surprises of -5.56% and 0.98%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Nu Skin Enterprises (NUS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Invesco High Yield Equity Dividend Achievers ETF (PEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PEY
Product Launches Aid Nu Skin (NUS), Macroeconomic Hurdles Ail
by Zacks Equity Research
Nu Skin (NUS) is benefiting from the Nu Vision 2025 strategy driven by a dynamic affiliate opportunity platform. However, escalating macroeconomic pressures are hampering key markets.